
CDMO: what it is, how FDA inspects contract facilities, and how to vet one
A CDMO develops and manufactures drugs for other companies under contract. This guide covers the definition, how FDA treats a contract facility as an extension of the sponsor under 21 CFR 200.10(b) and 211.22(a), and an Atlas analysis of FDA's inspection data: 100 classified CGMP inspections at 99 CDMO facilities from January 2025 to October 2026, 10% ending OAI against 16.0% at other drug facilities, the 21 CFR Part 211 sections FDA cites most at CDMOs, five OAIs that became warning letters, and a five-step check of a CDMO's inspection record.


















